Larimar Therapeutics stock: Price History and Returns
LRMRLarimar Therapeutics's share price fell by 23.1% a year over the last 10 years, 92.8% in total. Larimar Therapeutics does not pay a dividend at present, so the return came from the share price alone.
This shows what Larimar Therapeutics, Inc. has returned on the stock market in the past. Past returns say nothing about the future.
Daily figure as of 14 Nov 2026
Share Price Since 2014
How Larimar Therapeutics Has Performed
The stock has not yet recovered its largest drawdown of 99.8% between March 2015 and August 2022 and trades 99.5% below the high today. The best year was 2020 at +60.7%, the weakest 2015 at −79.6%. More calendar years ended with a loss than with a gain, 7 of 11 since 2015. From 2024 to 2025 the stock fell two years in a row.
At −1.6%, 2025 was above the 10-year average of −23.1% a year. Since the start of the year the stock is down 20.7%.
How Larimar Therapeutics Compares
Over 10 years Larimar Therapeutics trailed the S&P 500: −23.1% a year against +14.8% for the index, in US dollars. Over one year, Larimar Therapeutics trailed 66% of the 269 other stocks in the Biotechnology industry. Over five years the figure was 83%. The highest share price returns over five years in the Biotechnology industry came from Trevi Therapeutics, Rhythm Pharmaceuticals and ADMA Biologics.
| Period | Larimar Therapeutics | S&P 500 |
|---|---|---|
| 1 year | −8.2% | +12.6% |
| 5 years | −23.3% | +11.3% |
| 10 years | −23.1% | +14.8% |
Returns of Industry Peers
Among its industry peers, Enanta Pharmaceuticals led over one year (−6.2%) and Altimmune trailed furthest (−59.4%).
| Stock | 1 year | 5 years |
|---|---|---|
| Altimmune | −59.4% | −85.1% |
| Enanta Pharmaceuticals | −6.2% | −88% |
| Kyverna Therapeutics | −22.1% | no data |
| Autolus Therapeutics | −8.6% | −83% |
| MapLight Therapeutics | −49.2% | no data |
What Became of $1,000
Of $1,000 invested in Larimar Therapeutics 10 years ago, $72 is left today.
With dividends means each dividend is reinvested at the closing price on the ex-date, before taxes and costs. The index is represented by an accumulating ETF, dollar amounts at ECB rates. Industry figures are share price returns only, in each exchange's currency, as of 14 Nov 2026.
Returns by period
| Period | Total | Per year |
|---|---|---|
| 1 year | −8.2% | −8.2% |
| 3 years | +26.4% | +8.1% |
| 5 years | −73.5% | −23.3% |
| 10 years | −92.8% | −23.1% |
| Since 2014 | −98.7% | −29.7% |
Returns by calendar year
Figures as a table
| Year | Closing price | Return |
|---|---|---|
| 2026 to date | $3.02 | −20.7% |
| 2025 | $3.81 | −1.6% |
| 2024 | $3.87 | −14.9% |
| 2023 | $4.55 | +10.2% |
| 2022 | $4.13 | −61.7% |
| 2021 | $10.79 | −49.6% |
| 2020 | $21.41 | +60.7% |
| 2019 | $13.32 | −77.6% |
| 2018 | $59.40 | +7.1% |
| 2017 | $55.44 | +45.3% |
| 2016 | $38.16 | −49.4% |
| 2015 | $75.48 | −79.6% |
Peak price and largest drawdown
This is the pure share price return in US dollars from closing prices, adjusted for stock splits. Dividends come on top and are not included here.
Work out your own amount and period in the What-if calculatorData status and sources
- Score
- Daily value of 14 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.